Macchiarini Paolo
Department of Thoracic and Vascular Surgery, Heidehaus Hospital, Hannover Medical School, 70 Am Leineufer, D-30419 Hannover, Germany.
Thorac Surg Clin. 2004 May;14(2):229-40. doi: 10.1016/S1547-4127(04)00008-8.
Physicians' understanding of the anatomy, biology [9], and treatment outcome [12] for superior sulcus carcinoma has changed greatly during the last decade [2,3]. One of the major advances in this regard has been the introduction of anterior approaches for resection. These approaches increase the likelihood of complete resection and permit resection of tumors that were previously considered technically unresectable. Each approach must be understood in detail to avoid incomplete operations and life-threatening complications. These technical advances, with recent evidence that preoperative chemoradiotherapy leads to higher complete resection rates, overall survival, and local control than do radiation and surgery alone [32], have changed physicians' attitudes toward superior sulcus carcinomas, especially for those tumors (eg, T4) previously considered technically unresectable and oncologically incurable. It is hoped that, in the future, resection of disease invasion of the brachial plexus above C7 will be technically feasible [33], and that new drugs will reduce the risk of systemic relapse after resection.
在过去十年间,医生们对上叶沟癌的解剖学、生物学[9]及治疗结果[12]的认识发生了巨大变化[2,3]。这方面的一项重大进展是引入了前路切除术。这些手术方式提高了完全切除的可能性,并能切除之前被认为在技术上无法切除的肿瘤。必须详细了解每种手术方式,以避免手术不彻底及危及生命的并发症。这些技术进步,加上最近有证据表明,与单纯放疗和手术相比,术前放化疗能带来更高的完全切除率、总生存率及局部控制率[32],改变了医生们对上叶沟癌的态度,尤其是对于那些之前被认为在技术上无法切除且在肿瘤学上无法治愈的肿瘤(如T4)。人们希望,未来对C7以上臂丛神经受疾病侵犯的切除在技术上能够可行[33],并且新药将降低切除术后全身复发的风险。